

AMENDMENTS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A transdermal delivery system for **comprising:**
a drug selected from the group consisting of local anesthetic, immunosuppressive **drug,** and neurologically effective **drug, drugs,** as well as for polypeptides **polypeptide drug** and protein-based **drug, drugs,** ~~comprising a local anesthetic, immunosuppressive or neurologically effective drug, as well as a polypeptide or protein-based drug~~ in combination with water-miscible tetraglycol and water for dissolving said drug in hydrogel form, wherein said transdermal delivery system is in the form of a microemulsion, **and**
wherein said microemulsion is a system of water, oil, and amphiphile ~~which is a single optically isotropic and thermodynamically stable liquid solution.~~
2. (Original) A transdermal delivery system according to claim 1, further comprising an ionized polymer.
3. (Original) A transdermal delivery system according to claim 2, wherein said ionized polymer is selected from the group consisting of cationized guar gum, cellulose derivatives, acrylic polymers, polysaccharides, lipids, proteins and polyhydroxy compounds.
4. (Original) A transdermal delivery system according to claim 2, wherein said ionized polymer is a guar-based polymer, which serves as a gelling agent for said composition.
5. (Previously Presented) A transdermal delivery system according to claim 2, wherein said ionized polymer is the guar-based polymer hydroxypropyl guar hydroxypropyltrimonium chloride.
6. (Previously Presented) A transdermal delivery system according to claim 1, wherein said drug is selected from the group consisting of granisetron, lidocaine, and cyclosporine.
7. (Original) A transdermal delivery system according to claim 1, wherein said transdermal delivery system is in the form of a hydrogel patch.

8. (Previously Presented) A transdermal delivery system according to claim 1, further comprising a skin penetration enhancer.

9. (Previously Presented) A transdermal delivery system according to claim 8, wherein said skin penetration enhancer is a non-ionic surfactant.

10. (Previously Presented) A transdermal delivery system according to claim 9, wherein said non-ionic surfactant is selected from the group consisting of sorbitan sesquioleate, cetostearyl alcohol, polysorbate 60, sorbitan monostearate, sorbitan monooleate, polyoxyethylene 23 lauryl alcohol, glyceryl mono/di-oleate and mixtures thereof.

11. (Withdrawn) A transdermal delivery system for an alcohol-miscible drug comprising an alcohol-miscible drug in combination with water-miscible tetraglycol and water for dissolving said drug in hydrogel form, wherein said transdermal delivery system is in the form of a microemulsion

wherein said microemulsion is a system of water, oil, and amphiphile which is a single optically isotropic and thermodynamically stable liquid solution.

12. (Withdrawn) A topical delivery system for local anesthetic, immunosuppressive and neurologically effective drugs, as well as for polypeptides and protein-based drugs, comprising a local anesthetic, immunosuppressive or neurologically effective drug, as well as a polypeptide or protein-based drug in combination with water-miscible tetraglycol and water for dissolving said drug in hydrogel form, wherein said topical delivery system is in the form of a microemulsion

wherein said microemulsion is a system of water, oil, and amphiphile which is a single optically isotropic and thermodynamically stable liquid solution.